• Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, Nicole Gilroy, Raina MacIntyre, Benjamin Teh, Robert Weinkove, Jennifer Curnow, Jeff Szer, Anoop K Enjeti, David M Ross, Stephen Mulligan, Judith Trotman, Michael Dickinson, Hang Quach, Phillip Choi, Mark N Polizzotto, Constantine S Tam, P Joy Ho, Matthew Ku, Gareth Gregory, Shane Gangatharan, Greg Hapgood, Tara Cochrane, Chan Cheah, Simon Gibbs, Andrew Wei, Anna Johnston, Matthew Greenwood, H Miles Prince, Maya Latimer, Leanne Berkahn, Joel Wight, Tasman Armytage, and Nada Hamad.
• Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
• Intern Med J. 2021 May 1; 51 (5): 763-768.

AbstractAustralia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.© 2021 Royal Australasian College of Physicians.

16 keywords...

hide…